AI Chat
Loading data for ENVB — first visit, this takes a few seconds.

Enveric Biosciences, Inc.

ENVB · NasdaqCM · USD

1.48 +0.04 (2.78%)

At close: Sep 11, 2026, 8:00 PM

1.38 -2.52%

After-hours: 7:32 PM

Market Cap
$6.36M
Volume
104K

Enveric Biosciences, Inc. (ENVB) Stock Price, Analysis & Data

Intrinsic Value

Loading intrinsic value…

Analyst Forecast

Stock Forecasts →

Analyst forecast unavailable

12-month target · n/a analysts

Analyst Consensus: n/a

Interval:1D
Loading candles and signals…

Financial Performance

View financials →

Loading...

Latest Earnings

ReportedVs estimateYoY Change
Revenue$0n/an/a
EPS-$2,03+$0,73+98.94%

Next Earnings

View earnings details →

Metrics

Bid
1.08
Net Income (ttm)
-12.1M
1.11
-12.18
n/a
-1.01
P/B (ttm)
0.69
P/S (ttm)
n/a
Earnings Date
n/a
Ask
1.81
Volume
104,183
Avg. Volume (20D)
120,341
Open
1.48
Previous Close
1.44
Day's Range
1.41 - 1.54
52-Week Range
1.17 - 13.25
Ex-Dividend Date
Apr 23, 2008

About Enveric Biosciences, Inc.

View profile →
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts. Biotechnology · Healthcare

Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.

Industry Biotechnology
Sector Healthcare
IPO Date May 4, 2015
Employees 5
Stock Exchange NasdaqCM
Ticker Symbol ENVB